Kabra Drugs Limited (BOM:524322)

Kabra Drugs Income Statement

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Revenue	269.14	-	-	-	-	-
Cost of Revenue	232.74	-	-	-	-	-
Gross Profit	36.4	-	-	-	-	-
Selling, General & Admin	12.41	7.55	4.55	2.64	1.2	0.7
Other Operating Expenses	16.5	9.63	2.82	0.81	0.55	0.78
Operating Expenses	29.13	17.25	7.36	3.44	1.84	1.79
Operating Income	7.27	-17.25	-7.36	-3.44	-1.84	-1.79
Interest & Investment Income	-	-	-	0.06	-	-
Other Non Operating Income (Expenses)	8.35	6.4	-	-	-	-
EBT Excluding Unusual Items	15.62	-10.85	-7.36	-3.38	-1.84	-1.79
Gain (Loss) on Sale of Investments	-	-	-	-	-0.01	-0.01
Pretax Income	15.62	-10.85	-7.36	-3.38	-1.85	-1.8
Income Tax Expense	3.68	0.01	-	-	-	-
Net Income	11.94	-10.86	-7.36	-3.38	-1.85	-1.8
Net Income to Common	11.94	-10.86	-7.36	-3.38	-1.85	-1.8
Shares Outstanding (Basic)	19	11	4	4	4	4
Shares Outstanding (Diluted)	19	11	4	4	4	4
Shares Change (YoY)	617.12%	149.01%	-	-	-	-
EPS (Basic)	0.62	-0.99	-1.68	-0.77	-0.42	-0.41
EPS (Diluted)	0.62	-0.99	-1.68	-0.77	-0.42	-0.41
Free Cash Flow	-114.47	-47.58	-2.09	-3.54	-1.34	-2.49
Free Cash Flow Per Share	-5.95	-4.35	-0.47	-0.81	-0.30	-0.57
Gross Margin	13.53%	-	-	-	-	-
Operating Margin	2.70%	-	-	-	-	-
Profit Margin	4.44%	-	-	-	-	-
Free Cash Flow Margin	-42.53%	-	-	-	-	-
EBITDA	7.49	-17.18	-	-3.34	-1.74	-1.48
EBITDA Margin	2.78%	-	-	-	-	-
D&A For EBITDA	0.22	0.07	-	0.1	0.1	0.31
EBIT	7.27	-17.25	-7.36	-3.44	-1.84	-1.79
EBIT Margin	2.70%	-	-	-	-	-
Effective Tax Rate	23.57%	-	-	-	-	-
Revenue as Reported	277.49	6.4	-	0.06	-	-
Advertising Expenses	-	0.17	0.19	0.09	0.07	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.